Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

Withdrawn before enrolling · Phase 4

Conditions studied: Pulmonary Arterial Hypertension

In brief

It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular remodeling. The investigators believe that this study will help document the nature of beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular structure and function accompany clinical improvement.

Key facts

Study ID

NCT01508780

Run by

Massachusetts General Hospital

People needed

0

Starts

2012-05-01

Expected to finish

2014-02-01

Last updated by the study team

2014-02-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• WHO GROUP 1
• AGE 18-75
• Baseline 6-min walk distance (6MWD) between 200 and 450 m
• Diagnosed with pulmonary artery hypertension during right heart catheterization (Mean Pulmonary Artery Pressure > 25mmHg)
• General Exclusion Criteria
• Pregnant or nursing
• Acute or chronic illness other than those associated with PAH (collagen vascular disease, human immunodeficiency virus, or anorexigen use)
• Previously received any investigational medications, prostanoids, or phosphodiesterase inhibitors
• eGFR < 60
• Angina
• Syncope
• Failing right ventricle
• Hemoptysis

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.